Valeant Pharmaceuticals Intl (Put) (VRX) Stock Declined While Graham Capital Management LP Has Lowered Its Stake by $4.00 Million

April 23, 2018 - By Louis Casey

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) LogoInvestors sentiment decreased to 0.97 in 2017 Q4. Its down 0.02, from 0.99 in 2017Q3. It turned negative, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported. Guggenheim Capital Limited Liability has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Raymond James holds 0% or 75,441 shares in its portfolio. Canada Pension Plan Inv Board invested 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 10,000 are held by Keybank National Association Oh. Pnc Fincl Group Inc holds 0% or 10,839 shares in its portfolio. Axa invested in 26,353 shares. Intact Inv accumulated 125,500 shares. Alphamark Advsrs Limited Liability Company, a Kentucky-based fund reported 186 shares. Old Mutual Customised Solutions (Proprietary) Ltd reported 11,900 shares. Pictet Asset Mngmt Ltd stated it has 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Cibc Ww Mkts Incorporated holds 0.32% or 3.42M shares in its portfolio. New York-based Art Advsrs Ltd Liability has invested 0.09% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Bridgewater Assocs LP owns 41,855 shares. Blair William Company Il reported 131,941 shares. Clinton Gp has invested 0.18% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX).

Since March 8, 2018, it had 3 insider purchases, and 0 selling transactions for $876,370 activity. Herendeen Paul bought $241,470 worth of stock. $481,500 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares were bought by PAPA JOSEPH C.

Kenneth Tropin decreased its stake in Valeant Pharmaceuticals Intl (Put) (VRX) by 66.67% based on its latest 2017Q4 regulatory filing with the SEC. Graham Capital Management Lp sold 200,000 shares as the company’s stock declined 28.77% with the market. The hedge fund run by Kenneth Tropin held 100,000 shares of the health care company at the end of 2017Q4, valued at $2.08 million, down from 300,000 at the end of the previous reported quarter. Graham Capital Management Lp who had been investing in Valeant Pharmaceuticals Intl (Put) for a number of months, seems to be less bullish one the $6.12B market cap company. The stock increased 2.04% or $0.35 during the last trading session, reaching $17.53. About 3.81 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since April 23, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8 before the open. They expect $0.66 earnings per share, down 76.43 % or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.23 million for 6.64 P/E if the $0.66 EPS becomes a reality. After $0.98 actual earnings per share reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65 % negative EPS growth.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 14 analysts covering Valeant Pharma (NYSE:VRX), 2 have Buy rating, 4 Sell and 8 Hold. Therefore 14% are positive. Valeant Pharma had 28 analyst reports since October 30, 2017 according to SRatingsIntel. BMO Capital Markets maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Monday, October 30. BMO Capital Markets has “Hold” rating and $16.0 target. The rating was maintained by H.C. Wainwright on Tuesday, January 16 with “Hold”. Canaccord Genuity maintained it with “Hold” rating and $16.0 target in Monday, November 6 report. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, January 19 report. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Hold” rating by Susquehanna on Thursday, March 8. BTIG Research maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Monday, December 4 with “Hold” rating. The company was maintained on Friday, December 15 by Mizuho. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, November 7. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Sell” rating by Mizuho on Tuesday, November 7. CFRA downgraded the shares of VRX in report on Wednesday, February 28 to “Hold” rating.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.